Swedish molecular diagnostics company Elypta announced its role as a main partner in PREDI-LYNCH, a landmark European initiative aimed at transforming early cancer detection for individuals with Lynch Syndrome (LS).
The project Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome, PREDI-LYNCH in short, and coordinated by Oslo University Hospital (OUH), has received €13.6m in funding from the European Union HORIZON-MISS-2024-CANCER-01-03 mission on cancer (Grant Number 101213916).
The project aims to address the unmet need for an accurate, non-invasive, acceptable, and cost-effective method of detecting early-stage cancers in individuals with LS. Approximately 1 in 440 people of European ancestry are affected by LS, which is a hereditary genetic condition that increases the risk of developing cancer at an early age. It specifically increases the odds of colorectal, gynaecological, and urothelial cancers. With only 5% of the 2 million estimated LS carriers in Europe under cancer surveillance, there is an urgent need to improve cancer screening and monitoring.
Initiated on 1st May 2025 and coordinated by OUH, the ambitious PREDI-LYNCH project will see the cooperation between Elypta, OUH, and 26 other project partners, bringing together leading European oncology experts, biotechnology companies, and LS patient advocates. The 6-year project will evaluate multiple promising, non-invasive, liquid biopsy-based technologies in conjunction with artificial intelligence solutions for detecting early-stage cancers and deliver a multi-omic solution for affordable, accessible, and effective heritable cancer detection in LS.
In the PREDI-LYNCH project, Elypta will contribute its proprietary liquid biopsy tests for the early detection of cancers, based on the profiles of metabolomic glycosaminoglycans (GAGomes) as biomarkers in both plasma and urine, with the aim of stratifying at-risk LS carriers and detecting precancerous and early cancerous lesions.
“There is a clear and urgent need to improve cancer detection for Lynch Syndrome, and the PREDI-LYNCH project is designed to make a true difference in the lives of LS carriers. Elypta is honoured and excited to be a main contributing partner in this important project. We look forward to combining the results from Elypta’s GAG-based biomarker tests with the consortium’s expertise,” said Marianna Mirabelli, Director of Clinical Development at Elypta.
Read the Oslo University Hospital press release: https://www.ous-research.no/home/ous/news/26143
The project “Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome, PREDI-LYNCH" starts on May 1st and is funded by the European Commission Horizon Europe Mission on Cancer with 13.6 million Euro (project number 101213916). PREDI-LYNCH will run for six years (2025-2031), and the consortium consists of 28 partners from 16 European countries. The initiative is led by researcher Mev Dominguez Valentin at the Institute for Cancer Research, Oslo University Hospital (OUH).
Elypta is a Swedish cancer diagnostic company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detect cancer-specific signatures. Elypta is advancing a broad study program across different cancers with the leading indication being early detection of recurrence in renal cell carcinoma. www.elypta.com
